Trial · NCT04513639
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
NCT04513639, Phase 2, Phase 3, Recruiting, Oslo University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study. Trials, record NCT04513639. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04513639
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
- NCT number
- NCT04513639
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 176 participants, estimated
- Lead sponsor
- Oslo University Hospital
- Conditions
- Multiple Myeloma
- Interventions
- Early treatment of relapse with carfilzomib, dexamethasone, daratumumab, Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab
- First posted
- 2020-08-14
- Last updated
- 2025-03-20
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | 10 years | Median PFS of Arm A (MRD guided) vs Arm B (PD guided) defined as the time from randomization to disease progression or death due to any cause following 2.L treatment. |
| Primary | Overall survival (OS) | 11 years | Median OS of Arm A vs Arm B (MRD guided) defined as the time from randomization to death of any cause following 2.L treatment. |
| Primary | Minimal residual disease negativity after first line treatment | 30-45 days post consolidation | The number of participants who achieve MRD negativity measured by Euroflow NGF at 30-45 after consolidation therapy has ended |
| Secondary | Time-to-next treatment | 10 years | Time from end of first line treatment to start of 3.L therapy |
| Secondary | Minimal residual disease negativity during second line treatment | 6 months after starting second line treatment | The proportion of patients who achieve MRD negativity during 2.L treatment, monitored by MRD Euroflow NGF at 6 and 18 months in arm A and after achieving CR in arm B (first MRD testing after 6 months). |
| Secondary | Health-related quality of life (HRQOL) | 10 years | Patient reported outcome HRQOL forms will be filled out by patients at defined time points during the study and finally at relapse after 2.L therapy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41429779 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04513639
GET https://conductscience.org/api/trials/v1/NCT04513639/registered